全文获取类型
收费全文 | 4215篇 |
免费 | 509篇 |
国内免费 | 411篇 |
专业分类
电工技术 | 70篇 |
技术理论 | 1篇 |
综合类 | 528篇 |
化学工业 | 523篇 |
金属工艺 | 28篇 |
机械仪表 | 123篇 |
建筑科学 | 201篇 |
矿业工程 | 54篇 |
能源动力 | 18篇 |
轻工业 | 42篇 |
水利工程 | 39篇 |
石油天然气 | 92篇 |
武器工业 | 10篇 |
无线电 | 365篇 |
一般工业技术 | 133篇 |
冶金工业 | 389篇 |
原子能技术 | 3篇 |
自动化技术 | 2516篇 |
出版年
2023年 | 25篇 |
2022年 | 62篇 |
2021年 | 132篇 |
2020年 | 119篇 |
2019年 | 88篇 |
2018年 | 78篇 |
2017年 | 78篇 |
2016年 | 133篇 |
2015年 | 120篇 |
2014年 | 229篇 |
2013年 | 219篇 |
2012年 | 285篇 |
2011年 | 311篇 |
2010年 | 284篇 |
2009年 | 338篇 |
2008年 | 390篇 |
2007年 | 414篇 |
2006年 | 306篇 |
2005年 | 283篇 |
2004年 | 276篇 |
2003年 | 221篇 |
2002年 | 159篇 |
2001年 | 129篇 |
2000年 | 116篇 |
1999年 | 66篇 |
1998年 | 40篇 |
1997年 | 30篇 |
1996年 | 16篇 |
1995年 | 19篇 |
1994年 | 13篇 |
1993年 | 15篇 |
1992年 | 14篇 |
1991年 | 6篇 |
1990年 | 5篇 |
1989年 | 6篇 |
1988年 | 9篇 |
1986年 | 6篇 |
1985年 | 5篇 |
1984年 | 6篇 |
1982年 | 6篇 |
1980年 | 6篇 |
1978年 | 4篇 |
1966年 | 4篇 |
1965年 | 6篇 |
1963年 | 3篇 |
1961年 | 5篇 |
1960年 | 5篇 |
1959年 | 6篇 |
1955年 | 3篇 |
1954年 | 3篇 |
排序方式: 共有5135条查询结果,搜索用时 62 毫秒
1.
Dr. Jie Zang Dr. Fei Ye Dr. Sara M. Ø. Solbak Dr. Lars J. Høj Prof. Mingjie Zhang Prof. Anders Bach 《ChemMedChem》2021,16(6):949-954
Inhibition of PSD-95 has emerged as a promising strategy for the treatment of ischemic stroke, as shown with peptide-based compounds that target the PDZ domains of PSD-95. In contrast, developing potent and drug-like small molecules against the PSD-95 PDZ domains has so far been unsuccessful. Here, we explore the druggability of the PSD-95 PDZ1-2 domain and use fragment screening to investigate if this protein is prone to binding small molecules. We screened 2500 fragments by fluorescence polarization (FP) and validated the hits by surface plasmon resonance (SPR), including an inhibition counter-test, and found four promising fragments. Three ligand efficient fragments were shown by 1H,15N HSQC NMR to bind in the small hydrophobic P0 pockets of PDZ1-2, and one of them underwent structure-activity relationship (SAR) studies. Overall, we demonstrate that fragment screening can successfully be applied to PDZ1-2 of PSD-95 and disclose novel fragments that can serve as starting points for optimization towards small-molecule PDZ domain inhibitors. 相似文献
2.
Dr. Mpelegeng Victoria Bvumbi 《ChemMedChem》2020,15(23):2207-2219
Tuberculosis is one of the leading cause of death in the world, mainly due to the increasing number of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains. Factors such as the HIV pandemic contribute further. Also, the ineffectiveness of the chemotherapy in current use increases the mortality rate. Therefore, new and repurposed antituberculosis drugs are urgently needed for the treatment of MDR-TB, and riminophenazines are among those drugs that are being reinvestigated for their potential in the treatment of TB. This review delivers a brief historical account of riminophenazines, their general synthesis, mechanisms of action, and their physicochemical properties. The discussion is limited to those studies that investigated the activity of these compounds as antituberculosis agents. Given their unique properties, this review will be of great significance in giving direction towards the design and development of new riminophenazine analogues. 相似文献
3.
We define the emerging research field of applied data science as the knowledge discovery process in which analytic systems are designed and evaluated to improve the daily practices of domain experts. We investigate adaptive analytic systems as a novel research perspective of the three intertwining aspects within the knowledge discovery process in healthcare: domain and data understanding for physician- and patient-centric healthcare, data preprocessing and modelling using natural language processing and (big) data analytic techniques, and model evaluation and knowledge deployment through information infrastructures. We align these knowledge discovery aspects with the design science research steps of problem investigation, treatment design, and treatment validation, respectively. We note that the adaptive component in healthcare system prototypes may translate to data-driven personalisation aspects including personalised medicine. We explore how applied data science for patient-centric healthcare can thus empower physicians and patients to more effectively and efficiently improve healthcare. We propose meta-algorithmic modelling as a solution-oriented design science research framework in alignment with the knowledge discovery process to address the three key dilemmas in the emerging “post-algorithmic era” of data science: depth versus breadth, selection versus configuration, and accuracy versus transparency. 相似文献
4.
Ilaria Patruno Dr. Dawn Thompson Dr. Sergio Dall'Angelo Prof. Albert D. Windhorst Dr. Danielle J. Vugts Dr. Alex J. Poot Dr. Nimesh Mody Prof. Matteo Zanda 《ChemMedChem》2020,15(16):1579-1590
Fenretinide (4-HPR) is a synthetic derivative of all-trans-retinoic acid (ATRA) characterised by improved therapeutic properties and toxicological profile relative to ATRA. 4-HPR has been mostly investigated as an anti-cancer agent, but recent studies showed its promising therapeutic potential for preventing metabolic syndrome. Several biological targets are involved in 4-HPR's activity, leading to the potential use of this molecule for treating different pathologies. However, although 4-HPR displays quite well-understood multitarget promiscuity with regards to pharmacology, interpreting its precise physiological role remains challenging. In addition, despite promising results in vitro, the clinical efficacy of 4-HPR as a chemotherapeutic agent has not been satisfactory so far. Herein, we describe the preparation of a library of 4-HPR analogues, followed by the biological evaluation of their anti-cancer and anti-obesity/diabetic properties. The click-type analogue 3 b showed good capacity to reduce the amount of lipid accumulation in 3T3-L1 adipocytes during differentiation. Furthermore, it showed an IC50 of 0.53±0.8 μM in cell viability tests on breast cancer cell line MCF-7, together with a good selectivity (SI=121) over noncancerous HEK293 cells. Thus, 3 b was selected as a potential PET tracer to study retinoids in vivo, and the radiosynthesis of [18F] 3b was successfully developed. Unfortunately, the stability of [18F] 3b turned out to be insufficient to pursue imaging studies. 相似文献
5.
Hinako Udagawa Takato H. Yoneda Dr. Ryo Masuda Prof. Dr. Takaki Koide 《Chembiochem : a European journal of chemical biology》2019,20(16):2070-2073
d -Amino acid containing peptides are promising as drug lead compounds because of their expected higher stability in vivo. A heterochiral random peptide library called the one-bead–2n-peptide (OB2nP) library, which can display 2n peptide diastereomers per bead, has been developed. Through screening of the OB2nP library and subsequent binding assay among the peptide diastereomers synthesized in parallel by means of the SPOTs method, new heterochiral mimotopes for the anti-β-endorphin monoclonal antibody have been obtained. One mimotope was a new ligand for the μ-opioid receptor. The screening strategy enabled d -amino acid containing drug leads to be obtained efficiently by expanding searchable chemical space without increasing the experimental scale. 相似文献
6.
针对网络扫描工具在进行扫描时面临的溯源问题,提出了一种匿名网络扫描系统。首先将匿名系统与网络扫描工具结合以实现匿名扫描;然后在现有匿名系统的基础上实现了该系统的本地私有化;接着通过流量分析发现,Nmap的多进程扫描因为代理链的原因会变成单进程扫描而导致其扫描扫描性能较低;最后提出了一种基于多Namp进程并发的性能优化方案,将总体扫描任务分割为多个扫描任务,并分配给多个单独的Nmap进程并行运行。实验结果表明,该性能优化方案的扫描时延接近正常扫描情况下的时延,达到了提高匿名扫描系统性能的目的。因此,该优化后的网络匿名扫描系统在阻碍溯源的同时提升了扫描效率。 相似文献
7.
André Campaniço Dr. Marta P. Carrasco Dr. Mathew Njoroge Ronnett Seldon Prof. Kelly Chibale Dr. João Perdigão Prof. Isabel Portugal Prof. Digby F. Warner Prof. Rui Moreira Prof. Francisca Lopes 《ChemMedChem》2019,14(16):1537-1546
Herein we report the screening of a small library of aurones and their isosteric counterparts, azaaurones and N-acetylazaaurones, against Mycobacterium tuberculosis. Aurones were found to be inactive at 20 μm , whereas azaaurones and N-acetylazaaurones emerged as the most potent compounds, with nine derivatives displaying MIC99 values ranging from 0.4 to 2.0 μm . In addition, several N-acetylazaaurones were found to be active against multidrug-resistant (MDR) and extensively drug-resistant (XDR) clinical M. tuberculosis isolates. The antimycobacterial mechanism of action of these compounds remains to be determined; however, a preliminary mechanistic study confirmed that they do not inhibit the mycobacterial cytochrome bc1 complex. Additionally, microsomal metabolic stability and metabolite identification studies revealed that N-acetylazaaurones are deacetylated to their azaaurone counterparts. Overall, these results demonstrate that azaaurones and their N-acetyl counterparts represent a new entry in the toolbox of chemotypes capable of inhibiting M. tuberculosis growth. 相似文献
8.
Dr. Ala Jo Mingi Kim Dr. Jong In Kim Jaeyoung Ha Yoon Soo Hwang Hyunsung Nam Dr. Injae Hwang Dr. Jae Bum Kim Prof. Seung Bum Park 《ChemMedChem》2021,16(7):1104-1115
Obesity has become a pandemic that threatens the quality of life and discovering novel therapeutic agents that can reverse obesity and obesity-related metabolic disorders are necessary. Here, we aimed to identify new anti-obesity agents using a phenotype-based approach. We performed image-based high-content screening with a fluorogenic bioprobe (SF44), which visualizes cellular lipid droplets (LDs), to identify initial hit compounds. A structure-activity relationship study led us to yield a bioactive compound SB1501, which reduces cellular LDs in 3T3-L1 adipocytes without cytotoxicity. SB1501 induced the expression of gene products that regulate mitochondrial biogenesis and fatty acid oxidation in 3T3-L1 adipocytes. Daily treatment with SB1501 improved the metabolic states of db/db mice by reducing body fat mass, adipose tissue mass, food intake, and increasing glucose tolerance. The anti-obesity effect of SB1501 may result from perturbation of the PGC-1α–UCP1 regulatory axis in inguinal white adipose tissue and brown adipose tissue. These data suggest the therapeutic potential of SB1501 as an anti-obesity agent via modulating mitochondrial activities. 相似文献
9.
Dr. Pui-Ying Lam Dr. Peter Kutchukian Rajan Anand Dr. Jason Imbriglio Dr. Christine Andrews Hugo Padilla Anita Vohra Sarah Lane Dann L. Parker Jr. Dr. Ivan Cornella Taracido Dr. Douglas G. Johns Dr. Manu Beerens Dr. Calum A. MacRae John P. Caldwell Dr. Steve Sorota Dr. Aarti Asnani Dr. Randall T. Peterson 《Chembiochem : a European journal of chemical biology》2020,21(13):1905-1910
Doxorubicin is a highly effective chemotherapy agent used to treat many common malignancies. However, its use is limited by cardiotoxicity, and cumulative doses exponentially increase the risk of heart failure. To identify novel heart failure treatment targets, a zebrafish model of doxorubicin-induced cardiomyopathy was previously established for small-molecule screening. Using this model, several small molecules that prevent doxorubicin-induced cardiotoxicity both in zebrafish and in mouse models have previously been identified. In this study, exploration of doxorubicin cardiotoxicity is expanded by screening 2271 small molecules from a proprietary, target-annotated tool compound collection. It is found that 120 small molecules can prevent doxorubicin-induced cardiotoxicity, including 7 highly effective compounds. Of these, all seven exhibited inhibitory activity towards cytochrome P450 family 1 (CYP1). These results are consistent with previous findings, in which visnagin, a CYP1 inhibitor, also prevents doxorubicin-induced cardiotoxicity. Importantly, genetic mutation of cyp1a protected zebrafish against doxorubicin-induced cardiotoxicity phenotypes. Together, these results provide strong evidence that CYP1 is an important contributor to doxorubicin-induced cardiotoxicity and highlight the CYP1 pathway as a candidate therapeutic target for clinical cardioprotection. 相似文献
10.
Madhu Ramesh Dr. Pushparathinam Gopinath Prof. Thimmaiah Govindaraju 《Chembiochem : a European journal of chemical biology》2020,21(8):1052-1079
The global burden of Alzheimer's disease (AD) is growing. Valiant efforts to develop clinical candidates for treatment have continuously met with failure. Currently available palliative treatments are temporary and there is a constant need to search for reliable disease pathways, biomarkers and drug targets for developing diagnostic and therapeutic tools to address the unmet medical needs of AD. Challenges in drug-discovery efforts raise further questions about the strategies of current conventional diagnosis; drug design; and understanding of disease pathways, biomarkers and targets. In this context, post-translational modifications (PTMs) regulate protein trafficking, function and degradation, and their in-depth study plays a significant role in the identification of novel biomarkers and drug targets. Aberrant PTMs of disease-relevant proteins could trigger pathological pathways, leading to disease progression. Advancements in proteomics enable the generation of patterns or signatures of such modifications, and thus, provide a versatile platform to develop biomarkers based on PTMs. In addition, understanding and targeting the aberrant PTMs of various proteins provide viable avenues for addressing AD drug-discovery challenges. This review highlights numerous PTMs of proteins relevant to AD and provides an overview of their adverse effects on the protein structure, function and aggregation propensity that contribute to the disease pathology. A critical discussion offers suggestions of methods to develop PTM signatures and interfere with aberrant PTMs to develop viable diagnostic and therapeutic interventions in AD. 相似文献